Ferring Pharmaceuticals: Crohn Disease trials

The registry lists 10 Crohn Disease studies with Ferring Pharmaceuticals as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 4Phase 3 2Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study With Pentasa in Patients With Active Crohn's DiseaseTerminatedNCT00862121Phase 3Results posted
• Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's DiseaseCompletedNCT02193048
• Retrospective Data Analysis in Crohn's DiseaseCompletedNCT01363427
• Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)CompletedNCT00950105Phase 1
• Extension Study of Semapimod 60 mg IV x 3 DaysCompletedNCT00741910Phase 2
• Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's DiseaseCompletedNCT00740103Phase 2
• Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus PlaceboCompletedNCT00739986Phase 2
• The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active "Drug: Crohn's Disease"TerminatedNCT00245505Phase 3
• A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s DiseaseCompletedNCT00225810Phase 4
• CNI-1493 for Treatment of Moderate to Severe Crohn's DiseaseTerminatedNCT00038766Phase 2